ES2040209T3 - Procedimiento de preparacion de formulaciones de nifedipina solida de alta disponibilidad biologica y con efecto sostenido, y las formulaciones obtenidas. - Google Patents

Procedimiento de preparacion de formulaciones de nifedipina solida de alta disponibilidad biologica y con efecto sostenido, y las formulaciones obtenidas.

Info

Publication number
ES2040209T3
ES2040209T3 ES198686201704T ES86201704T ES2040209T3 ES 2040209 T3 ES2040209 T3 ES 2040209T3 ES 198686201704 T ES198686201704 T ES 198686201704T ES 86201704 T ES86201704 T ES 86201704T ES 2040209 T3 ES2040209 T3 ES 2040209T3
Authority
ES
Spain
Prior art keywords
formulations
policy
substantial
solution
nifedipine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES198686201704T
Other languages
English (en)
Inventor
Massimo Calanchi
Piergiorgio Rossi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Adare Pharmaceuticals SRL
Original Assignee
Eurand Italia SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eurand Italia SpA filed Critical Eurand Italia SpA
Application granted granted Critical
Publication of ES2040209T3 publication Critical patent/ES2040209T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heat Treatment Of Sheet Steel (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
  • Superconductors And Manufacturing Methods Therefor (AREA)

Abstract

EL OBJETIVO DE LA PRESENTE INVENCION ES UN PROCESO QUE PERMITE EL INCREMENTO DE LA BIODISPONIBILIDAD EN FORMULACIONES SOLIDAS DE NIFEDIPINA Y SUS DERIVADOS. CONSISTE EN LA DISOLUCION DE LA SUBSTANCIA ACTIVA JUNTO CON POLIETILENGLICOL EN UN DISOLVENTE COMUN, ABSORBIENDO ENTONCES ESTA SOLUCION EN UN MICRONIZADO, EXCIPIENTE INERTE, SOLUBLE EN LOS JUGOS GASTROINTESTINALES, Y FINALMENTE, COPRECIPITANDO LA SUBSTANCIA ACTIVA Y EL POLIETILENGLICOL POR EXAPORACION DEL SOLVENTE. LA GRAN SUPERFICIE EXCIPIENTE EN LA QUE LA SOLUCION ES ABSORBIDA, Y EN PRESENCIA DEL POLIETILENGLICOL, QUE FACILITA LA DISTRIBUCION HOMOGENEA DE LA SOLUCION SOBRE LA SUPERFICIE, PERMITE QUE LA SUBSTANCIA ACTIVA SE PRECIPITE HASTA LLEGAR A CONVERTIRSE EN PARTICULAS MUY FINAS. SE DESCRIBE OTRO METODO DE HOMOGENIZACION DEL EXCIPIENTE INERTE MICRONIZADO CON NIFEDIPINA MICRONIZADA Y OBSORCION DE LA MEZCLA EN UNA SOLUCION DE POLIETILENGLICOL Y SUBSIGUIENTE EVAPORACION DEL DISOLVENTE.
ES198686201704T 1985-10-15 1986-10-02 Procedimiento de preparacion de formulaciones de nifedipina solida de alta disponibilidad biologica y con efecto sostenido, y las formulaciones obtenidas. Expired - Lifetime ES2040209T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT22494/85A IT1187751B (it) 1985-10-15 1985-10-15 Procedimento per la preparazione di formulazioni solidi di nifedipina ad elevata biodisponibilita' e ad effetto prolungato e formulazioni cosi' ottenute

Publications (1)

Publication Number Publication Date
ES2040209T3 true ES2040209T3 (es) 1993-10-16

Family

ID=11197023

Family Applications (1)

Application Number Title Priority Date Filing Date
ES198686201704T Expired - Lifetime ES2040209T3 (es) 1985-10-15 1986-10-02 Procedimiento de preparacion de formulaciones de nifedipina solida de alta disponibilidad biologica y con efecto sostenido, y las formulaciones obtenidas.

Country Status (18)

Country Link
US (1) US4880623A (es)
EP (1) EP0220760B1 (es)
JP (1) JPH0811731B2 (es)
KR (1) KR940006320B1 (es)
AT (1) ATE66367T1 (es)
AU (1) AU590622B2 (es)
CA (1) CA1280976C (es)
DE (1) DE3680989D1 (es)
DK (1) DK168691B1 (es)
ES (1) ES2040209T3 (es)
FI (1) FI87424C (es)
GR (1) GR3003150T3 (es)
HK (1) HK12595A (es)
IT (1) IT1187751B (es)
NO (1) NO172168C (es)
NZ (1) NZ217841A (es)
PT (1) PT83522B (es)
ZA (1) ZA867767B (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8601624D0 (sv) * 1986-04-11 1986-04-11 Haessle Ab New pharmaceutical preparations
US5215752A (en) * 1988-03-17 1993-06-01 Vectorpharma International S.P.A. Pharmaceutical tablets and capsule granulates of scleroglucan and active substance
US5028433A (en) * 1988-11-30 1991-07-02 Banyu Pharmaceutical Co., Ltd. Readily absorbable drug formulation of NB-818
GB8903328D0 (en) * 1989-02-14 1989-04-05 Ethical Pharma Ltd Nifedipine-containing pharmaceutical compositions and process for the preparation thereof
HU203041B (en) * 1989-03-14 1991-05-28 Egyt Gyogyszervegyeszeti Gyar Process for producing pharmaceutical compositions of controlled releasing factor containing nifedipin
GB9025251D0 (en) * 1990-11-20 1991-01-02 Solomon Montague C Nifedipine dosage forms
US5145859A (en) * 1991-03-20 1992-09-08 Case Western Reserve University Methods of treating interstitial cystitis and urethral syndrome
US5271944A (en) * 1991-04-05 1993-12-21 Biofor, Ltd. Pharmacologically enhanced formulations
US5302397A (en) * 1991-11-19 1994-04-12 Amsden Brian G Polymer-based drug delivery system
DK0557244T3 (da) * 1992-02-17 1996-04-01 Siegfried Ag Pharma Dosisformer med forlænget afgivelse af aktivt stof
IL104192A (en) * 1992-02-17 1998-01-04 Siegfried Ag Pharma Pharmaceutical dosage forms having prolonged release rate of zero order of the active ingredient
WO1994005262A1 (en) * 1992-09-10 1994-03-17 F.H. Faulding & Co. Limited Sustained release matrix composition
US6726930B1 (en) * 1993-09-09 2004-04-27 Penwest Pharmaceuticals Co. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5455046A (en) * 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5773025A (en) * 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
US5543099A (en) * 1994-09-29 1996-08-06 Hallmark Pharmaceutical, Inc. Process to manufacture micronized nifedipine granules for sustained release medicaments
US5618845A (en) * 1994-10-06 1997-04-08 Cephalon, Inc. Acetamide derivative having defined particle size
IL123505A (en) 1996-07-08 2004-12-15 Penwest Pharmaceuticals Compan Sustained release matrix for high-dose insoluble drugs
IT1284604B1 (it) * 1996-09-27 1998-05-21 Roberto Valducci Composizioni farmaceutiche a rilascio controllato per somministrazione orale contenenti nifedipina come sostanza attiva
US5922352A (en) * 1997-01-31 1999-07-13 Andrx Pharmaceuticals, Inc. Once daily calcium channel blocker tablet having a delayed release core
US5837379A (en) * 1997-01-31 1998-11-17 Andrx Pharmaceuticals, Inc. Once daily pharmaceutical tablet having a unitary core
US6056977A (en) 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
US6485748B1 (en) 1997-12-12 2002-11-26 Andrx Pharmaceuticals, Inc. Once daily pharmaceutical tablet having a unitary core
US8236352B2 (en) 1998-10-01 2012-08-07 Alkermes Pharma Ireland Limited Glipizide compositions
US8293277B2 (en) 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
US7521068B2 (en) 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
CA2352211C (en) * 1999-09-30 2009-03-24 Edward Mendell Co., Inc. Sustained release matrix systems for highly soluble drugs
CA2395331C (en) 1999-12-23 2009-01-06 Pfizer Products Inc. Pharmaceutical compositions providing enhanced drug concentrations
IL134701A0 (en) 2000-02-23 2001-04-30 J P M E D Ltd Homogeneous solid matrix containing vegetable proteins
US7198795B2 (en) 2000-09-21 2007-04-03 Elan Pharma International Ltd. In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
EP1269994A3 (en) * 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
MXPA03011935A (es) * 2001-06-22 2004-03-26 Pfizer Prod Inc Composiciones farmaceuticas que contienen conjuntos de polimero y farmaco.
DE10142417A1 (de) * 2001-08-31 2003-03-20 Molecular And Clinical Drug Re Arzneimittel
DE10142416A1 (de) * 2001-08-31 2003-03-20 Molecular And Clinical Drug Re Verfahren zur Herstellung von Lösungen
WO2003033462A2 (en) * 2001-10-15 2003-04-24 The Regents Of The University Of Michigan Systems and methods for the generation of crystalline polymorphs
GB0205253D0 (en) * 2002-03-06 2002-04-17 Univ Gent Immediate release pharmaceutical granule compositions and a continuous process for making them
US20040048931A1 (en) * 2002-07-12 2004-03-11 Craig Heacock Modafinil pharmaceutical compositions
CA2511992A1 (en) * 2003-02-24 2004-09-10 Mallinckrodt Inc. Process for preparing benzhydrylthioacetamide
WO2004087102A2 (en) * 2003-03-26 2004-10-14 Teva Pharmaceutical Industries Ltd. A process for preparing a pharmaceutical active ingredient with high specific surface area
US20040253308A1 (en) * 2003-04-29 2004-12-16 Barr Laboratories, Inc. Surface-treated modafinil particles
CA2644069A1 (en) * 2006-02-28 2007-09-07 Helicon Therapeutics, Inc. Therapeutic piperazines as pde4 inhibitors
US20080181966A1 (en) * 2006-10-18 2008-07-31 Cephalon, Inc. Modafinil pharmaceutical compositions
CN102014918A (zh) * 2007-04-20 2011-04-13 太阳医药工业有限公司 由微量沉淀产生的药学组合物
RU2629843C1 (ru) * 2016-05-24 2017-09-04 федеральное государственное автономное образовательное учреждение высшего образования Первый Московский государственный медицинский университет имени И.М. Сеченова Министерства здравоохранения Российской Федерации (Сеченовский университет) Способ получения мази нифедипина (варианты)

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO98434A (es) * 1959-04-30
US3920809A (en) * 1973-11-05 1975-11-18 Lilly Co Eli Dibenzo(b,d)pyranone dispersions
US3988439A (en) * 1973-11-05 1976-10-26 Eli Lilly And Company Dibenzo[b,d]pyranone dispersions
DE2400819C2 (de) * 1974-01-09 1982-04-22 Bayer Ag, 5090 Leverkusen Verfahren zur Herstellung fester Zubereitungen von schwerlöslichen Arzneimittelwirkstoffen in feinster Verteilung
US4151273A (en) * 1974-10-31 1979-04-24 The Regents Of The University Of California Increasing the absorption rate of insoluble drugs
GB1579818A (en) * 1977-06-07 1980-11-26 Yamanouchi Pharma Co Ltd Nifedipine-containing solid preparation composition
EP0001247A1 (en) * 1977-09-14 1979-04-04 Kanebo, Ltd. Pharmaceutical preparation containing nifedipine and a method for producing the same.
JPS55129221A (en) * 1979-03-29 1980-10-06 Kaken Pharmaceut Co Ltd Preparation of oral preparation containing hardly soluble medicine
CA1146866A (en) * 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
US4311694A (en) * 1979-12-31 1982-01-19 American Cyanamid Company Amorphous coprecipitates of 4-(monoalkylamino) benzoic acid and derivatives and certain water-soluble materials
DE3033919A1 (de) * 1980-09-09 1982-04-22 Bayer Ag, 5090 Leverkusen Feste arzneizubereitungen enthaltend nifedipin und verfahren zu ihrer herstellung
JPS58116414A (ja) * 1981-12-23 1983-07-11 Yamanouchi Pharmaceut Co Ltd ニカルジピン持続性製剤用球形顆粒およびその製造法
DE3318649A1 (de) * 1983-05-21 1984-11-22 Bayer Ag, 5090 Leverkusen Zweiphasenformulierung
NL194389C (nl) * 1984-06-14 2002-03-04 Novartis Ag Werkwijze voor het bereiden van een vaste dispersie van een farmaceutisch actief middel dat een lage oplosbaarheid in water heeft, in een vaste matrix van een in water oplosbaar polyalkyleenglycol als drager.
IT1178511B (it) * 1984-09-14 1987-09-09 Pharmatec Spa Procedimento per la preparazione di una forma solida per uso orale a base di nifedipina con rilascio
DE3438830A1 (de) * 1984-10-23 1986-04-30 Rentschler Arzneimittel Nifedipin enthaltende darreichungsform und verfahren zu ihrer herstellung

Also Published As

Publication number Publication date
ATE66367T1 (de) 1991-09-15
DK168691B1 (da) 1994-05-24
IT1187751B (it) 1987-12-23
KR870003779A (ko) 1987-05-04
NO172168C (no) 1993-06-16
HK12595A (en) 1995-02-03
DK481186A (da) 1987-04-16
GR3003150T3 (en) 1993-02-17
US4880623A (en) 1989-11-14
AU6383286A (en) 1987-04-16
EP0220760A2 (en) 1987-05-06
PT83522A (en) 1986-11-01
NZ217841A (en) 1990-01-29
DK481186D0 (da) 1986-10-08
FI87424C (fi) 1993-01-11
IT8522494A0 (it) 1985-10-15
ZA867767B (en) 1987-06-24
NO172168B (no) 1993-03-08
PT83522B (pt) 1988-11-30
KR940006320B1 (ko) 1994-07-16
DE3680989D1 (de) 1991-09-26
FI864151A0 (fi) 1986-10-14
NO864060D0 (no) 1986-10-13
EP0220760B1 (en) 1991-08-21
EP0220760A3 (en) 1987-09-23
JPS62167727A (ja) 1987-07-24
JPH0811731B2 (ja) 1996-02-07
CA1280976C (en) 1991-03-05
FI87424B (fi) 1992-09-30
FI864151A (fi) 1987-04-16
NO864060L (no) 1987-04-21
AU590622B2 (en) 1989-11-09

Similar Documents

Publication Publication Date Title
ES2040209T3 (es) Procedimiento de preparacion de formulaciones de nifedipina solida de alta disponibilidad biologica y con efecto sostenido, y las formulaciones obtenidas.
AR011410A1 (es) Una formulacion liquida que contiene gonadotrofinas, un metodo para preparar una composicion liquida de gonadotrofinas, un cartucho que contiene una formulacion liquida esteril, un dispositivo para administrar la formulacion y utilizacion de la formulacion que contiene la gonadotrofinas para la elab
ES2057604T3 (es) Enantiomero r de n-propargil-1-aminoindano, su preparacion y composiciones farmaceuticas que lo contienen.
DK0395329T4 (da) Sammensætning i form af et skum indeholdende 5-aminosalicylsyre til intrarektal administration
AR015360A1 (es) Proceso para la manufactura de una composicion farmaceutica para reducir o prevenir los efectos de la inflamacion; dicha composicion farmaceutica y unelemento para aplicar la composicion farmaceutica en dicho proceso
ES2325506T3 (es) Procedimiento para la preparacion de principios activos farmaceuticos (api) anhidros e hidratados; composiciones farmaceuticas estables preparadas a partir de los mismos y usos de dichas composiciones.
ES2051782T3 (es) Una composicion farmaceutica de liberacion lenta.
ES2038359T3 (es) Procedimiento para la obtencion de formulaciones inyectables intramusculares de inhibidores de girasa.
ES2024668B3 (es) Microparticulas que comportan un polimero biodegradable que controla la liberacion de un principio activo antimalarico, composiciones farmaceuticas que lo contienen y procedimiento de preparacion
EP0319964B1 (en) Film-formation-type antifungal preparation
ES2093118T3 (es) Procedimiento para la preparacion de comprimidos o comprimidos recubiertos de pelicula.
SE7702232L (sv) Forfarande for framstellning av substituerade 8-azapurinderivat
ES2040774T3 (es) Procedimiento para la preparacion de una formulacion medicamentosa.
ES496664A0 (es) Un procedimiento para la preparacion de una penicilina adap-tada para inyeccion intramuscular.
FI802960A (fi) Piperidinderivat av 4,5-dialkyl-3-hydroxipyrrol-2-karboxylsyraestrar foerfarande foer deras framstaellning och farmaceutiska preparat innehaollande dessa
US20150209428A1 (en) Pharmaceutical compositions for topical delivery of photosensitizers and uses thereof
Nazarkar et al. Formulation of transdermal patches of miconazole nitrate and assesment for drug release
ATE4808T1 (de) Piperidinderivate von 3-hydroxy-thiophen-2carbons[ureestern,ihre herstellung und diese enthaltende pharmazeutische zubereitungen.
PE20050863A1 (es) Forma de administracion transdermica, liquida o semisolida que contiene sustancia activa sensible a la luz, estable a los rayos ultravioletas
UY25089A1 (es) Vacunas no acuosas
RU2014085C1 (ru) Антимикробный состав
ES512748A0 (es) "procedimiento para la preparacion de comprimidos a base del antibiotico fosfomicina".
JPS6425720A (en) Percutaneous absorption pharmaceutical
IT943062B (it) Procedimento per la rapida distru zione biologica delle pope esauri te di barbabietole
CU21970A1 (es) Procedimiento para la preparación de formas farmacéuticas de acción prolongada